10% Owner Michael Skaff and V-Co Investors 3 LLC Acquire $7.17M in Vivos Therapeutics Stock and Warrants
VVOS sits 23% above its 52-week low of $1.085 on light trading volume (0.4× avg).
Summary
10% owners Michael C. Skaff and V-Co Investors 3 LLC acquired $7.17 million in Vivos Therapeutics stock and warrants, including a debt conversion, representing over 50% of the company's market cap.
Key Events · Ownership and Investor Activity · VVOS
-
Significant Insider Acquisition
10% owners Michael C. Skaff and V-Co Investors 3 LLC acquired $7,170,000 worth of Vivos Therapeutics securities, including common stock and various warrants, on March 31, 2026.
-
Substantial Capital Infusion
The acquisition includes the conversion of a $1.4 million bridge promissory note into common stock and the purchase of pre-funded warrants, Series A common stock warrants, and Series B common stock warrants, all priced at $1.34 per unit/share.
-
Major Stake Relative to Market Cap
The total transaction value of $7.17 million represents over 50% of the company's current market capitalization, indicating a very significant capital commitment.
-
Expands on Prior Disclosure
This Form 4 provides detailed transaction data, significantly expanding on the $2.39 million private placement previously disclosed in a Schedule 13D filed on the same day by V-Co Investors.
Analysis · VVOS · Industrial Applications And Services
This Form 4 filing reveals a substantial capital commitment by 10% owners Michael C. Skaff and V-Co Investors 3 LLC, totaling $7.17 million in Vivos Therapeutics securities. This significant investment, representing over 50% of the company's market capitalization, includes the conversion of a $1.4 million bridge promissory note into common stock and the acquisition of additional common stock, pre-funded warrants, and Series A and B common stock warrants. While a Schedule 13D filed on the same day disclosed a $2.39 million private placement, this Form 4 provides a much more comprehensive picture of the total capital infusion, indicating a strong vote of confidence and significantly bolstering the company's financial runway, which is critical for a nano-cap entity.
How filings like this one have moved
In the 30 days to Oct 22, 2026, 46.1% of the 284 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -0.53%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, VVOS was trading at $1.33 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $13.8M. The 52-week trading range was $1.09 to $7.95. This filing was assessed with positive market sentiment and an importance score of 9 out of 10.